World Journal of Gastroenterology · 2020 · 31 citations · 34 references
MedicinePharmacotherapyBone MetabolismCalcium HomeostasisRheumatologyBone Density RegulationBone HealthBone Metabolism DisordersBone QualityBone Quality AssessmentOsteoporosisBone DensitometryBone Formation MarkersBone Mineral DensityBone Mineral Density DeclineBone Quality IndicesDrug Effects On Bone DensityOsteoporotic FracturesTartrate-resistant Acid Phosphatase Activity
BACKGROUND: Effective treatment of osteoporosis is essential for improving morbidity and health-related quality of life in chronic liver disease (CLD) patients. Denosumab has been shown to increase bone mineral density (BMD) and decrease the risk of osteoporotic fracture in the general population. However, there are few reports evaluating the efficacy of denosumab in CLD patients. AIM: To investigated the effects and safety of denosumab in CLD patients with osteoporosis. METHODS: Sixty CLD patients with osteoporosis were subcutaneously administered denosumab once every 6 mo. The study period for evaluating efficacy and safety was 12 mo. Changes from baseline in BMD at the lumbar spine, femoral neck, and total hip were evaluated at 12 mo of denosumab treatment. Bone turnover and quality were assessed by measuring serum tartrate-resistant acid phosphatase-5b (bone resorption marker), serum total procollagen type I N-terminal propeptide (bone formation maker), and plasma pentosidine (bone quality marker). RESULTS: = 0.010). No patients experienced fractures and moderate-to-severe adverse events, except for transient hypocalcemia. CONCLUSION: Denosumab treatment was safe and increased BMD, suppressed bone turnover, and improved bone quality marker levels in CLD patients with osteoporosis, irrespective of differences in baseline characteristics.
34
Hisataka Yasuda, Nobuyuki Shima, N. Nakagawa et al. · Proceedings of the National Academy of Sciences · 1998 · 4.3K citations
Denosumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung, E. Michael Lewiecki, Stanley Cohen et al. · New England Journal of Medicine · 2006 · 1.2K citations · Full text
Henry G. Bone, Rachel B. Wagman, Maria Luisa Brandi et al. · The Lancet Diabetes & Endocrinology · 2017 · 961 citations · Full text